FindTrial
Sign In

Abnormal Drug Reaction Surveillance in Patients Receiving Chemotherapy at a State-Level Cancer Institute

Adverse Drug Reaction Monitoring In Patients Undergoing Chemotherapy At A State-Level Cancer Institute - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/03/064191
Enrollment
100
Registered
2024-03-15
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D499- Neoplasm of unspecified behavior of unspecified site Health Condition 2: C00-D49- Neoplasms

Interventions

Intervention1: NIL: NIL

Sponsors

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Male and female patients of all age groups receiving cancer chemotherapy and developing at least one ADR. Patients willing to join the study after giving a written informed consent.

Exclusion criteria

Exclusion criteria: Patients receiving concurrent radiotherapy along with chemotherapy. Patient not willing to give consent for the study.

Design outcomes

Primary

MeasureTime frame
To detect and assess the adverse drug reactions in patients undergoing cancer chemotherapy using WHO-UMC scale for causality.Timepoint: One time enquiry—

Secondary

MeasureTime frame
To assess the preventability of ADRs using Modified Schumock and Thornton scaleTimepoint: One time Enquiry;To assess the severity of ADRs using the Modified Hartwig and Siegel ScaleTimepoint: One time enquiry—

Countries

India

Contacts

Public ContactDr. Dixit Goyal

GOVERNMENT MEDICAL COLLEGE, AMRITSAR

navyug69@gmail.com9878634358

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026